Nexalis Therapeutics Limited has released a press release.
Prospectus - Non-Renounceable Rights Issue Offer
Filed with ASX ·
6ix hasn’t read this filing yet.
Nexalis Therapeutics Limited on 6ix
Earlier from Nexalis Therapeutics
- Drug Development Pipeline Bolstered and Capital Raise
- Trading Halt
- Sep25 Quarterly Activities Report
- Sep25 Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
Later from Nexalis Therapeutics
- $12.6m Facility to Drive SRX-25 Development
- IRX Overview Presentation - SRX-25 and Nexalis
- Dec25 Appendix 4C Cash Flow Report
- Dec25 Quarterly Activities Report
- Preliminary Final Report
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics